{"DataElement":{"publicId":"5797697","version":"1","preferredName":"Radiation Therapy Iobenguane Iodine I-131 Dose Reduced Or Therapy Delayed Or Prolonged Dose Modification Descriptive Text","preferredDefinition":"The text that describes the details of I-131 MIBG dose reduction or treatment delays.","longName":"MIBG_DS_RDC_TP_DLY_TXT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5796832","version":"1","preferredName":"Radiation Therapy Iobenguane Iodine I-131 Dose Reduced Or Therapy Delayed Or Prolonged Dose Modification","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.:A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells._A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production._An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An indication that a therapy was either delayed or prolonged._Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","longName":"2403872v1.00:5796830v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2403872","version":"1","preferredName":"Radiation Therapy","preferredDefinition":"use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively.","longName":"C15313","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"004438C0-4DCB-6342-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-08","modifiedBy":"ONEDATA","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5796830","version":"1","preferredName":"Iobenguane Iodine I-131 Dose Reduced Or Therapy Delayed Or Prolonged Dose Modification","preferredDefinition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.:A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.:An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:No Value Exists:Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","longName":"5796830v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iobenguane","conceptCode":"C87757","definition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Iodine I-131","conceptCode":"C1639","definition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Dose Reduced","conceptCode":"C49505","definition":"An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapy Delayed or Prolonged","conceptCode":"C50425","definition":"An indication that a therapy was either delayed or prolonged.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose Modification","conceptCode":"C54346","definition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E41DEAC-2FA9-3099-E053-F662850A71AD","latestVersionIndicator":"Yes","beginDate":"2017-04-28","endDate":null,"createdBy":"HLAINGY","dateCreated":"2017-04-28","modifiedBy":"ONEDATA","dateModified":"2017-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435016","version":"1","preferredName":"Chemotherapy Regimen","preferredDefinition":"Drug therapy using two or more drugs given together or separately for a combined effect.","longName":"C12218","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B9F7-9264-25C9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E41DEAC-2FBA-3099-E053-F662850A71AD","latestVersionIndicator":"Yes","beginDate":"2017-04-28","endDate":null,"createdBy":"HLAINGY","dateCreated":"2017-04-28","modifiedBy":"KUMMEROA","dateModified":"2023-09-15","changeDescription":"Workflow and Registration Status Changed per Brenda Duggan; 05.16.18; reviewed and released 12/22/2021.","administrativeNotes":"2023.9.15 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2181231","version":"1","preferredName":"Descriptive Text","preferredDefinition":"The text that provides a description of a topic.","longName":"DESCR_TXT","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":"1","maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D3B72801-8C4C-3772-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2004-02-19","modifiedBy":"GDEEN","dateModified":"2022-05-31","changeDescription":"3/22/22 jk added \"Qualified\" RS as part of MCL quarterly content review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Provide details of unplanned","type":"Preferred Question Text","description":"Provide details of unplanned dose reductions or treatment delays during this reporting period:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E427784-EC8C-676B-E053-F662850AE096","latestVersionIndicator":"Yes","beginDate":"2017-04-28","endDate":null,"createdBy":"HLAINGY","dateCreated":"2017-04-28","modifiedBy":"MAESKEB","dateModified":"2021-12-22","changeDescription":"Reviewed and Released 12/22/2021.; Workflow and Registration Status Changed per Brenda Duggan; 05.16.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}